The United Kingdom's medicines regulator has added a very rare sight-threatening condition to its safety advice for semaglutide products, including Ozempic, Wegovy and Rybelsus. The February 5, 2026 update concerns non-arteritic anterior ischemic optic neuropathy, or NAION.
The Medicines and Healthcare products Regulatory Agency said NAION may affect up to 1 in 10,000 people taking semaglutide. Its review estimated approximately one additional case for every 10,000 person-years of treatment among adults with type 2 diabetes. One person-year means one person treated for one year.
This is a serious signal because NAION can cause sudden, painless loss of vision, usually in one eye. It is also a rare event in a population that may already have diabetes, high blood pressure, high cholesterol or other risk factors. The regulator's conclusion calls for clear warnings and urgent assessment, not a claim that every reported case was caused by the medicine.
Regulators Reviewed More Than One Observational Study
The European Medicines Agency's safety committee reached the same classification in 2025 after reviewing clinical trials, post-marketing reports, non-clinical data and published medical research. It recommended listing NAION as a very rare side effect in the product information for semaglutide medicines.
Large epidemiological studies reviewed by European and UK regulators suggested that adults with type 2 diabetes exposed to semaglutide had about twice the risk of NAION as people not taking the medicine. Expressed as an absolute difference, the review estimated roughly one extra case per 10,000 people treated for a year.
The absolute and relative figures answer different questions. A doubling sounds large, but the event starts from a low background rate. The absolute estimate shows why regulators describe it as very rare while still treating sudden symptoms as an emergency.
Evidence is not perfectly consistent. A 2026 systematic review pooled six observational studies involving more than 4.8 million people. Its adjusted analyses did not demonstrate a consistent overall increase in NAION compared with non-GLP-1 treatments. The authors rated much of the evidence low or very low certainty because results varied between studies and could be affected by confounding and outcome misclassification.
A New Reporting Signal Is Not a Fivefold Incidence Rate
A separate British Journal of Ophthalmology study examined more than 30 million reports in the US Food and Drug Administration's adverse-event reporting system from 2017 through 2024. Among 31,774 reports involving semaglutide, the researchers found a stronger disproportionate reporting signal for ischemic optic neuropathy with Wegovy than with Ozempic. They also found a stronger signal among men than women.
Those comparisons do not mean that a Wegovy user is known to face five times the real-world incidence of an Ozempic user. The database collects suspected adverse events submitted after treatment. It does not contain a complete denominator showing how many people used each product without an event, and reports can be affected by publicity, prescribing patterns and the different dates on which products entered the market.
The study's authors presented the finding as a possible dose- and formulation-dependent concern requiring prospective evaluation. Wegovy and Ozempic contain the same active ingredient but are approved for different uses and can be prescribed at different doses. The analysis can identify a pattern worth testing; it cannot establish that formulation or dose caused an individual patient's optic-nerve injury.
That limit also matters when comparing people prescribed semaglutide with other patients. Diabetes and obesity are associated with vascular conditions that may independently raise NAION risk. Researchers must separate the effect of the medicine from the health conditions that led to its use.
Sudden Vision Changes Require Urgent Assessment
NAION occurs when blood flow to the front of the optic nerve is reduced. The MHRA describes the usual presentation as sudden, painless blurring, cloudiness or loss of vision, typically affecting one eye at a time. A rapidly worsening change can also be a warning sign.
The agency advises people who experience sudden vision loss, including partial loss, or rapidly worsening eyesight during semaglutide treatment to attend eye casualty or an emergency department urgently. An ophthalmologist may then examine the optic nerve and determine the cause.
The instruction to discontinue semaglutide applies when NAION is confirmed. The safety notice does not tell every Ozempic, Wegovy or Rybelsus user to stop treatment pre-emptively. Unsupervised changes can carry their own risks for people using semaglutide for type 2 diabetes, weight management or cardiovascular risk reduction.
Patients can discuss the warning during a prescribing appointment or medication review, particularly if they have existing eye disease or vascular risk factors. That conversation should cover the medicine's expected benefits, the rarity and seriousness of NAION, the symptoms that demand urgent care and the patient's individual medical history.
The Safety Response Must Match the Evidence
The MHRA had received three UK spontaneous reports suggestive of NAION from semaglutide's first authorization in 2018 through August 1, 2025. It estimated that roughly 10.2 million packs had been dispensed over the preceding five years, although pack counts are not patient counts or treatment duration. A report means someone suspected a connection; it does not confirm one.
That small number does not erase the signal, just as a high reporting-odds ratio does not convert it into a common event. Regulators used the total evidence to require updated product information and a clear emergency pathway. Researchers now need prospective studies with reliable exposure data, confirmed diagnoses and suitable comparison groups to calculate risk more precisely.
The responsible response is neither reassurance by omission nor panic by headline. Patients deserve to know that NAION can threaten sight, that the recognized risk is very rare and exactly what symptom requires immediate action. Prescribers need to make that warning routine without turning an uncertain association into a universal instruction to abandon effective treatment.
The sharper test is whether the safety system can convert a rare signal into useful behavior. A label that names the condition, an urgent referral when vision changes and careful follow-up of confirmed cases can reduce preventable harm now. Inflated risk claims and unsupervised stop advice do the opposite: they replace pharmacovigilance with fear.